Lower efficacy of omalizumab in older adults with chronic spontaneous urticaria
Lower efficacy of omalizumab in older adults with chronic spontaneous urticaria
复制标题
奥马珠单抗对患有慢性自发性荨麻疹的老年人的疗效较低
DOI：
10.1111/1346-8138.16370
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Fukunaga Atsushi
中科院分区：
文献类型：
--
作者：
Kitao Rikuma;Oda Yoshiko;Washio Ken;Tai Yukimasa;Ono Ryusuke;Nishigori Chikako;Fukunaga Atsushi
已知奥马珠单抗可有效治疗对H1抗组胺药反应不足的慢性自发性荨麻疹（CSU）。尽管许多报告描述了治疗前生物标志物来预测奥马珠单抗在CSU中的疗效，但很少有报告研究年龄与奥马珠单抗疗效之间的关系。因此，我们的目的是调查奥马珠单抗的反应和年龄之间的关系。这项回顾性研究包括2017年4月至2021年3月期间接受三个连续奥马珠单抗疗程的52名CSU患者。使用荨麻疹控制试验将参与者分类为应答者或非/部分应答者，以评估第12周的临床变量。女性发生率倾向于较高，平均年龄和中位疾病持续时间倾向于较低，与非/部分缓解者相比，缓解者无显著性差异。此外，两组之间过去报告为预测因子的血清免疫球蛋白E水平、嗜碱性粒细胞计数、嗜酸性粒细胞计数、d-二聚体和自体血清皮肤试验结果无显著差异。有趣的是，当患者被分类为年龄<65岁或≥65岁时，≥65岁组的患者对奥马珠单抗的反应显著低于年龄<65岁组。这些发现表明，医生应该记住，CSU患者的年龄可能是奥马珠单抗治疗效果的预测因素。
Omalizumab is known to be effective in treating chronic spontaneous urticaria (CSU) with an inadequate response to H1‐antihistamine. Although many reports have described pre‐treatment biomarkers to predict the efficacy of omalizumab in CSU, there are few reports that examined the relationship between age and the therapeutic effectiveness of omalizumab. Thus, we aimed to investigate the relationship between response to omalizumab and age. This retrospective study comprised 52 CSU patients receiving three consecutive omalizumab courses during the period from April 2017 to March 2021. Participants were categorized as responders or non/partial responders using the urticaria control test to evaluate clinical variables on week 12. The female rate tended to be higher, and the mean age and the median disease duration tended to be lower with no significance in responders compared with in non/partial responders. In addition, they exhibited no significant differences regarding serum immunoglobulin E levels, basophil counts, eosinophil counts,d‐dimer, and autologous serum skin test results reported as predictor in the past between two groups. Interestingly, when patients were categorized as age <65 years or ≥65 years, those in the ≥65 years group had a significantly lower response to omalizumab than those aged <65 years. These findings suggest that physicians should keep in mind that the age of their CSU patients may be a predictor of the therapeutic efficacy of omalizumab.
登录
查看更多内容
DOI：
10.1016/j.jaip.2019.08.025
发表时间：
2020-01-01
影响因子：
9.4
作者：
Kolkhir, Pavel;Church, Martin K.;Maurer, Marcus
通讯作者：
Maurer, Marcus
影响因子：
5
作者：
Chuamanochan, Mali;Kulthanan, Kanokvalai;Nuchkull, Piyavadee
通讯作者：
Nuchkull, Piyavadee
FcεRI 介导的嗜碱性粒细胞反应性的改善反映了奥马珠单抗对慢性自发性荨麻疹的快速反应。
DOI：
--
发表时间：
2020
期刊：
影响因子：
--
作者：
Yoshiko Oda;Atsushi Fukunaga;Ken Washio;Shinya Imamura;Mayumi Hatakeyama;Kanako Ogura;Chikako Nishigori
通讯作者：
Chikako Nishigori
影响因子：
3.1
作者：
Kim, Bo Ri;Yang, Seungkeol;Youn, Sang Woong
通讯作者：
Youn, Sang Woong
影响因子：
3.6
作者：
Martina, Emanuela;Damiani, Giovanni;Offidani, Annamaria
通讯作者：
Offidani, Annamaria